NGD-4715

From Self-sufficiency
Jump to: navigation, search
NGD-4715
File:NGD-4715 structure.png
Systematic (IUPAC) name
1-(3,4-dimethoxybenzyl)-4-(5-bromo-6-methoxypyridin-2-yl)piperazine
Chemical data
Formula C19H24BrN3O3
Molar mass 422.315[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

NGD-4715 is a drug being developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal studies it has anxiolytic, antidepressant and anorectic effects,[1] and it has successfully passed Phase I clinical trials in humans.[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. Drugs of the Future. 2007;32(9):809.
  2. Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity. Business Wire. May 2 2007